all report title image
  • Published On : Aug 2022
  • Code : CMI5192
  • Industry : Pharmaceutical
  • Pages : 156
  • Formats :

The rare kidney cancer nephroblastoma, sometimes called wilms' tumor, typically affects young people. Children with nephroblastoma are most frequently affected between the ages of 3 and 4, cases after age 5 are substantially less prevalent. Although it can occasionally be seen in both kidneys at the same time, nephroblastoma typically only affects one kidney. When cells experience DNA errors, cancer develops. The errors cause the cells to grow and divide uncontrollably. The accumulating cells then form a tumor. This process takes place in the kidney cells in nephroblastoma.

Global nephroblastoma treatment market is estimated to be valued at US$ 1,653.0 million in 2022 and is expected to exhibit a CAGR of 4.6% during the forecast period (2022-2030).

Figure 1.Global Nephroblastoma Treatment Market Share (%), by Type, 2022

Nephroblastoma Treatment  | Coherent Market Insights

Increasing approvals from regulatory bodies to key players for nephroblastoma treatment in market are expected to drive growth of the nephroblastoma treatment market.

Key players in market are focused on receiving approvals from regulatory bodies for drugs used to treat nephroblastoma, which is expected to drive the market growth over the forecast period. For instance, in May 2022, Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) had accepted the company's Investigational New Drug (IND) application for the evaluation of CUE-102, its second interleukin 2 (IL-2)-based CUE-100 series biologic, in a dose escalation and expansion monotherapy Phase 1 trial, which would have a starting dose of 1 mg/kg for the treatment of wilms’ tumor 1 (WT1)-positive recurrent/metastatic cancers, with initial focus on gastric, pancreatic, ovarian and colon cancers.

CMI table icon

Nephroblastoma Treatment Market Report Coverage

Report Coverage Details
Base Year: 2021 Market Size in 2022: US$ 1,653.0 Mn
Historical Data for: 2017 to 2020 Forecast Period: 2022 to 2030
Forecast Period 2022 to 2030 CAGR: 4.6% 2030 Value Projection: US$ 2,366.5 Mn
Geographies covered:
  • North America: U.S. and Canada
  • Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
  • Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
  • Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
  • Middle East: GCC Countries, Israel, and Rest of Middle East
  • Africa: South Africa, North Africa, and Central Africa
Segments covered:
  • By Type: Favorable histology, Anaplastic histology
  • By Drug Type: Dactinomycin (Cosmegen), Doxorubicin (Adriamycin), Vincristine (Vincasar PFS, Oncovin), Cyclophosphamide (Cytoxan, Neosar), Etoposide (Toposar, VePesid), Irinotecan (Camptosar), Others
  • By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Companies covered:

Merck & Co., Inc., Recordati Rare Diseases, Pfizer Inc., Sun Pharmaceutical Industries Ltd., Cipla Inc., Actiza Pharmaceutical Private Limited, Teva Pharmaceutical Industries Ltd., Alvogen, Accord Healthcare Ireland Ltd., Baxter, Amneal Pharmaceuticals LLC., Cadila Pharmaceuticals Ltd., and Xediton Pharmaceuticals

Growth Drivers:
  • Increasing approvals from regulatory bodies to key players for the nephroblastoma treatment
  • Rising research and development activities by key players for the treatment of nephroblastoma
Restraints & Challenges:
  • High treatment cost of nephroblastoma

Figure 2.Global Nephroblastoma Treatment Market Share (%), by Distribution Channel, 2022

Nephroblastoma Treatment  | Coherent Market Insights

Rising research and development activities by key players for the treatment of nephroblastoma are expected to drive the market growth during the forecast period.

Key players in market are focused on carrying out research and development activities for the development of drugs used to treat nephroblastoma, which is expected to drive the market growth over the forecast period. For instance, the Children's Oncology Group, a clinical trials group supported by the National Cancer Institute, is currently studying the effect of combination chemotherapy and surgery in treating young patients with wilms tumor. As of August 4, 2022, the study is currently in phase 3 of its clinical trial and the study is expected to be completed by November 2023.

Global Nephroblastoma Treatment Market– Impact of Coronavirus (COVID-19) Pandemic

Since the COVID-19 virus outbreak in December 2019, the disease has spread to over 100 countries across the globe and the World Health Organization had declared it a public health emergency on January 30, 2020.

COVID-19 can affect the economy in three main ways: by directly affecting production and demand, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to nationwide lockdowns, several countries, such as China, India, Saudi Arabia, UAE, Egypt, and others, are facing problems with regards to the transportation of products from one place to another.

The COVID-19 pandemic had a negative economic impact on the global nephroblastoma treatment market, owing to the delay in routine screening of cancer. For instance, according to an article published by the National Center for Biotechnology Information, in September 2021, on March 16, 2020, the U.K., postponed routine screening for cancer in response to the COVID-19 pandemic.

Global Nephroblastoma Treatment Market: Restraint

The major factor that hinders growth of the global nephroblastoma treatment market includes high treatment cost of nephroblastoma. For instance, according to an article published by the American Society of Clinical Oncology, in November 2018, the cost for a full course of treatment and follow-up was determined to be between US$ 1,490 and US$ 2,093 for a patient with nephroblastoma according to the study at the Butaro Cancer Center of Excellence (BCCOE), located at the Butaro District Hospital in rural northern Rwanda, Central Africa.

Key Players

Major players operating in the global nephroblastoma treatment market include Merck & Co., Inc., Recordati Rare Diseases, Pfizer Inc., Sun Pharmaceutical Industries Ltd., Cipla Inc., Actiza Pharmaceutical Private Limited, Teva Pharmaceutical Industries Ltd., Alvogen, Accord Healthcare Ireland Ltd., Baxter, Amneal Pharmaceuticals LLC., Cadila Pharmaceuticals Ltd., and Xediton Pharmaceuticals.

Nephroblastoma, also known as Wilms tumor, is the most prevalent kind of renal cancer among pediatrics. Although the exact cause of Wilms tumor is unknown, genetic changes related to the normal embryological development of the genitourinary tract are thought to be to the reason behind the tumor. The most typical childhood abdominal cancer, wilms tumor, often manifests between the ages of 3 and 5. Nephrectomy and systemic chemotherapy are typically used to treat wilms tumors, while some regimens start the chemotherapy first and perform the nephrectomy afterwards. Vincristine and dactinomycin are most frequently used in the initial chemotherapy.  Carboplatin, cyclophosphamide, etoposide, and doxorubici are also used. Some common symptoms of wilms tumor include belly pain, swelling in the belly, fever, nausea, lack of appetite, constipation, and shortness of breath. There are two kinds of wilms tumors, favorable histology and unfavorable or anaplastic histology.

Market Dynamics

Increasing research and development activities by various organizations and researchers to develop treatment options for nephroblastoma are expected to drive the market growth over the forecast period. For instance, according to the findings of the study published in the Journal of Clinical Oncology in September 2021, the COSMIC-021 study (NCT03170960), a multicenter, phase 1b, open-label study, the combination of cabozantinib plus atezolizumab demonstrated encouraging clinical activity in patients with advanced renal cell carcinoma (RCC). Robust clinical activity was observed across dose levels and histologic subtypes. The safety profile with the combination was tolerable with dose modification and comparable to previous reports. The findings of the study were published by Sumanta K. Pal, MD, Clinical Professor, Department of Medical Oncology & Therapeutics Research, Co-director, Kidney Cancer Program, City of Hope Comprehensive Cancer Center in Duarte, CA, U.S. 

Key features of the study:

  • This report provides in-depth analysis of the global nephroblastoma treatment market, and provides market size (US$ Million) and compound annual growth rate (CAGR%) for the forecast period (2022–2030), considering 2021 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends,  regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global nephroblastoma treatment market  based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
  • Key companies covered as a part of this study include Merck & Co., Inc., Recordati Rare Diseases, Pfizer Inc., Sun Pharmaceutical Industries Ltd., Cipla Inc., Actiza Pharmaceutical Private Limited, Teva Pharmaceutical Industries Ltd., Alvogen, Accord Healthcare Ireland Ltd., Baxter, Amneal Pharmaceuticals LLC., Cadila Pharmaceuticals Ltd., and Xediton Pharmaceuticals
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The global nephroblastoma treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts1
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global nephroblastoma treatment market

Detailed Segmentation:

  • Global Nephroblastoma Treatment Market, By Type:
    • Favorable histology 
    • Anaplastic histology  
  • Global Nephroblastoma Treatment Market, By Drug Type:
    • Dactinomycin (Cosmegen)
    • Doxorubicin (Adriamycin) 
    • Vincristine (Vincasar PFS, Oncovin)
    • Cyclophosphamide (Cytoxan, Neosar)
    • Etoposide (Toposar, VePesid)
    • Irinotecan (Camptosar)
    • Others
  • Global Nephroblastoma Treatment Market, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies 
    • Online Pharmacies 
  • Global Nephroblastoma Treatment Market, By Region:
    • North America
      • By Country
        • U.S.
        • Canada
    • Latin America 
      • By Country
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • By Country
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Country
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • By Country
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Type
        • Favorable histology 
        • Anaplastic histology  
      • By Drug Type
        • Dactinomycin (Cosmegen)
        • Doxorubicin (Adriamycin) 
        • Vincristine (Vincasar PFS, Oncovin)
        • Cyclophosphamide (Cytoxan, Neosar)
        • Etoposide (Toposar, VePesid)
        • Irinotecan (Camptosar)
        • Others
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies 
        • Online Pharmacies  
      • By Region/Country
        • South Africa
        • Central Africa
        • North Africa
  • Company Profiles
    • Merck & Co., Inc.
      • Company Highlights
      • Products Portfolio
      • Key Highlights
      • Financial Performance
      • Strategies
    • Recordati Rare Diseases
    • Pfizer Inc.
    • Sun Pharmaceutical Industries Ltd.
    • Cipla Inc.
    • Actiza Pharmaceutical Private Limited
    • Teva Pharmaceutical Industries Ltd.
    • Alvogen
    • Accord Healthcare Ireland Ltd.
    • Baxter
    • Amneal Pharmaceuticals LLC.
    • Cadila Pharmaceuticals Ltd.
    • Company Highlights
    • Xediton Pharmaceuticals

 “*” marked represents similar segmentation in other categories in the respective section.

Frequently Asked Questions

The global nephroblastoma treatment market size is estimated to be valued at US$ 1,653.0 million in 2022 and is expected to exhibit a CAGR of 4.6% between 2022 and 2030.
Factors such as increasing approvals from regulatory bodies to key players for the nephroblastoma treatment and rising research and development activities by key players for the treatment of nephroblastoma are expected to drive the market growth.
Favorable histology is the leading type segment in the market.
The major factor hampering growth of the market includes high treatment cost of nephroblastoma.
Major players operating in the market include Merck & Co., Inc., Recordati Rare Diseases, Pfizer Inc., Sun Pharmaceutical Industries Ltd., Cipla Inc., Actiza Pharmaceutical Private Limited, Teva Pharmaceutical Industries Ltd., Alvogen, Accord Healthcare Ireland Ltd., Baxter, Amneal Pharmaceuticals LLC., Cadila Pharmaceuticals Ltd., and Xediton Pharmaceuticals.

Related Reports

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo